CCAAT/Enhancer binding protein β silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson's disease.

Morales-Garcia, Jose A

CCAAT/Enhancer binding protein β silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson's disease. [electronic resource] - Scientific reports 10 2017 - 13526 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

2045-2322

10.1038/s41598-017-13269-4 doi


Animals
Apoptosis--drug effects
CCAAT-Enhancer-Binding Protein-beta--antagonists & inhibitors
Cells, Cultured
Disease Models, Animal
Dopaminergic Neurons--cytology
Humans
Male
Mesencephalon--cytology
Oxidopamine--pharmacology
Parkinson Disease--metabolism
Pars Compacta--drug effects
RNA Interference
RNA, Small Interfering--metabolism
Rats
Rats, Wistar
alpha-Synuclein--metabolism